Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Jazz Pharmaceuticals PLC (JAZZ) P/E Ratio & Valuation History
Jazz Pharmaceuticals (JAZZ) trades at 18.4x trailing earnings and 3.3x sales. Its P/E of 18.4x is above its 5-year median of 9.5x. Its forward P/E is 10.3x. The median P/E across 4 similar companies is 18.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 78.6% higher over the next year. Its free cash flow yield is 4.6%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 18.4x |
| Forward P/E | 10.3x |
| Price to sales | 3.3x |
| Price to book | 3.7x |
| EV/EBITDA | 16.6x |
| Price to FCF | 21.7x |
| EV/FCF | 26.7x |
| PEG | 1.0 |
| FCF yield | 4.6% |
Historical Medians
Against its 10-year medians, its P/E is 84.0% above 10.0x, its P/S is 13.8% above 2.9x and its P/B is 42.3% above 2.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 18.4x | 9.5x | 10.0x |
| P/S | 3.3x | 2.3x | 2.9x |
| P/B | 3.7x | 2.3x | 2.6x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 5.8x in 2024 to 24.1x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $170.00 | 24.1x | 2.4x | 2.4x |
| 2024 | $123.15 | 5.8x | 1.9x | 1.9x |
| 2023 | $123.00 | 6.7x | 2.1x | 2.3x |
| 2022 | $159.31 | 12.1x | 2.7x | 3.3x |
| 2021 | $127.40 | 7.8x | 2.5x | 2.0x |
| 2020 | $165.05 | 13.2x | 3.9x | 2.6x |
| 2019 | $149.28 | 9.2x | 3.9x | 2.7x |
| 2018 | $123.96 | 9.1x | 3.9x | 2.7x |
| 2017 | $134.65 | 12.2x | 5.0x | 3.0x |
| 2016 | $109.03 | 10.7x | 4.5x | 3.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About JAZZ
What is JAZZ's forward P/E ratio?
Jazz Pharmaceuticals has a forward P/E ratio of 10.3x.
Is JAZZ stock overvalued?
GNG's valuation label for JAZZ is Fairly valued. Its P/E of 18.4x compares with a median of 18.5x across 4 similar companies.
What is JAZZ's price to sales ratio?
Jazz Pharmaceuticals has a price to sales ratio of 3.3x.
What is Jazz Pharmaceuticals's average P/E ratio over 5 years?
Jazz Pharmaceuticals's median P/E over the last 5 years is 9.5x, from 60 month-end values through Oct 2026.
What is JAZZ's PEG ratio?
Jazz Pharmaceuticals has a PEG ratio of 1.0.
JAZZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts